The first patient in Centrexion Therapeutics Corp.'s Phase 3 VICTORY-1 clinical trial has been dosed with CNTX-4975, a synthetic trans-capsaicin injection for the treatment of chronic moderate to severe pain due to knee osteoarthritis.